

**Additional information under art. 33, par. 1, item 6 of  
Ordinance № 2 from 17.09.2003 of "Sopharma" AD as at 30 June  
2012**

1. Information about changes in accounting policies during the reporting period, the reasons for them and how they affect the financial results and equity of the issuer - *no changes*.

2. Information about changes in the economic group of the issuer, if such a group is present - *No changes*.

3. Information about the results of organizational changes within the issuer, such as restructuring, sale of companies from the group, in-kind contributions from companies, rental property, long-term investments, closure of business.

On 10 April.2012 the Board of Directors of "Sopharma" AD decided to sell 8,976 registered ordinary shares with voting rights, representing 51% stake in ZAO "Rostbalkanpharm" city of Azov, Rostov Region, Russian Federation, distributed in a total of 17,600 shares of the issue with state registration № 1-01-58454-R.

The Board of Directors of Sopharma AD (the "Company") took the decision to establish the "Sopharma Ukraine OOD" company with headquarters in Kiev, Ukraine and with share capital of 1,000,000 / one million / UAH. The aim of the company is to optimize the trading business in Ukraine.

The book value of the investments by company is as follows:

		<b>30.06.2012</b>	<b>Interest</b>	<b>31.12.2011</b>	<b>Interest</b>
		<b>BGN '000</b>	<b>%</b>	<b>BGN '000</b>	<b>%</b>
Sopharma Trading AD	Bulgaria	32 267	81.31	32 273	81.33
Unipharm AD	Bulgaria	19 449	49.99	19 449	49.99
Bulgarian Rose Sevtopolis AD	Bulgaria	8 729	49.99	8 729	49.99
Briz OOD	Latvia	6 262	51.00	6 262	51.00
Vitamina AD	Ukraine	6 187	99.56	6 187	99.56
Ivanchich and sons	Serbia	5 739	51.00	5 739	51.00
Biopharm Engineering AD	Bulgaria	3 451	69.43	3 451	69.43
Momina Krepost AD	Bulgaria	2 896	49.94	2 891	49.85
Pharmalogistica AD	Bulgaria	1 911	76.54	1 911	76.54
Sopharma Buildings REIT	Bulgaria	1 128	42.64	1 128	42.64
Electroncommerce EOOD	Bulgaria	384	100.00	384	100.00
Extab Corporation	USA	47	80.00	47	80.00
Sopharma Warsaw EOOD	Poland	7	100.00	7	100.00
Rostbalkanpharm AD	Russia	-	51.00	4	51.00
Sopharma Zdrovit AD	Poland	-	50.01	-	50.01
Sopharma Poland Ltd.	Poland	-	60.00	-	60.00
Sopharma USA	USA	-	100.00	-	100.00
		<b>88 457</b>		<b>88 462</b>	
Paid but not registered capital increase in subsidiaries		5 339		-	
<b>Total</b>		<b>93 796</b>		<b>88 462</b>	

Sopharma has direct or indirect control over the above listed companies.

4. Opinion of the governing body regarding the feasibility of the published estimates of the results for the current financial year, taking into account the results of the current quarter as well as information on the factors and circumstances that will affect the achieving of the projected results for at least the next quarter - *no update of the forecast results*.

5. For public companies - data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter;

SHAREHOLDERS	Number of shares /%/ 30 June 2012	Number of shares /%/ 31 March 2012
„Donev Investment Holding” AD, EIK 0831915121, Sofia, Positano Str. № 12	32 478 776 /24,61%/	32 425 897 /24,57%/
*„Telecomplect” AD, EIK 0831643753, Sofia, Totleben Blvd. № 69-73	0	26 948 052 /20,42%/
“Telecomplect Invest” AD, EIK 201653294, Sofia, Positano Str. № 12	26 948 052 /20,42%/	0
„Finance Consulting Company” EOOD EIK 121414242 Sofia, Khan Krum Str. 10	21 440 855 /16,24%/	21 440 855 /16,24%/
**“Gramercy select master fund”, 236349, Mary Street, Georgetown, Grand Cayman, CY1-9005	0	8 383 458 /6,35%/
**“Gramercy emerging markets fund”, 0000081961, W.S WALKER&CO., CALEDONIA HOUSE, GEORGETOWN, GRAND CAYMAN, CAYMAN ISL	0	7 780 192 /5,89%/
Universal Pension Fund “Doverie” AD, EIK 130474628 Sofia, Dunav Str. 5	8 871 543 /6,72%/	5 517 649 /4,18%/

\* Under the Plan for transformation of "Telekomplekt" AD in accordance with art. 262a, par. 2 of the Commercial Act through separation by formation of "Telekomplekt Invest" AD and registration in the Commercial Register under №164 905 from 29 July 2011 the ownership of 26,948,052 /20.42%/ shares of "Sopharma" AD shall be transferred to the newly formed company. As of 30 June 2012 the shares of "Telekomplekt Invest" Ltd. are registered in the Central Depository.

**\*\* Gramercy Select Master Fund, USA, Georgetown and Gramercy Emerging Markets Fund, USA, Georgetown** closed their position in the capital of "Sopharma" AD. The date of registration of the transaction with the Central Depository is 09 April 2012.

6. For public companies - data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter;...

Members of the Board of Directors	Number of shares 30 June 2012	Number of shares 31 March 2012
1. Ognian Ivanov Donev	0	0
2. Vessela Liubenova Stoeva	0	0
3. Andrey Liudmilov Breshkov	11000	11000
4. "Unipharm" AD	221166	221166
5. Ognian Kirilov Palaveev	54320	54320
6. Alexander Viktorov Chaushev	86514	85514

Ognian Kirilov Palaveev is a newly elected member of the Board by a decision of the AGM held on 19 June 2012 in place of "Unipharm" AD.

7. No information on pending judicial, administrative or arbitration proceedings relating to liabilities or receivables amounting to at least 10 percent of the equity of the issuer.

8. Information on loans granted by the issuer or their subsidiary, provided guarantees or commitments to a single person or a subsidiary thereof, including to related persons with indication of the nature of the relationship between the issuer and the person, the amount of the outstanding principal, the interest rate, the maturity, the size of commitment, the terms and conditions.

*Long-term loans granted to related parties* are as follows:

	<b>30.06.2012</b>	<b>31.12.2011</b>
	<b>BGN '000</b>	<b>BGN '000</b>
Subsidiaries	5 636	15 340
Companies under a common control through key managing personnel	743	729
Companies – main shareholders	-	0
<b>Total</b>	<b>6 379</b>	<b>16 069</b>

The terms and conditions of the long-term loans granted to related parties are as follows:

Currency	Contracted amount '000	Maturity	Interest %	30.06.2012		31.12.2011	
				BGN'000	BGN'000 including interest	BGN'000	BGN'000 including interest
<i>to subsidiaries</i>							
USD	3 000	25.01.2015	9.80%	1 573	5	5 845	1 311
EUR	2 770	21.01.2013	6.10%	-	-	5 732	314
USD	1 000	25.01.2015	9.80%	2 154	602	2 022	510
USD	3 000	25.01.2015	9.80%	1 909	511	1 741	381
<i>to Companies under common indirect control through key managing personnel</i>							
BGN	1 100	31.12.2014	8.08%	743	20	729	1
				<b>6 379</b>	<b>1 138</b>	<b>16 069</b>	<b>2 517</b>

The long-term loans granted to related parties are not secured by collateral.

*Loans granted to related parties by type of related party are as follows:*

	30.06.2012 BGN '000	31.12.2011 BGN '000
Receivables from companies under common control through key managing personnel	49 715	36 088
Companies under common indirect control	14 102	12 737
<i>Impairment of trade loans</i>	<i>(1 861)</i>	<i>(1 783)</i>
	12 241	10 954
Companies – main shareholders	8 180	14 458
Subsidiaries	6 332	267
<b>Total</b>	<b>76 468</b>	<b>61 767</b>

The terms of the granted loans to related companies are as follows:

Currency	Contracted amount '000	Maturity	Interest %	30.06.2012		31.12.2011	
				BGN'000	BGN'000 including interest	BGN'000	BGN'000 including interest
<i>to Companies under common indirect control through key managing personnel</i>							
EUR	7 200	25.10.2012	4.50%	16 779	400	14 164	82
BGN	14 287	31.12.2012	8.30%	15 668	1 249	14 492	662
BGN	18 495	31.08.2012	8.08%	11 841	319	-	-
BGN	2 477	31.12.2012	8.08%	2 765	384	2 669	288
BGN	945	31.12.2012	8.08%	1 042	243	1 011	211
EUR	1 581	31.12.2012	5.50%	794	-	3 387	295
BGN	1 050	31.12.2012	8.08%	607	7	53	3
BGN	190	31.12.2012	8.08%	219	29	211	21
BGN	120	10.07.2012	8.08%	-	-	101	-
<i>to companies – main shareholders</i>							
EUR	4 035	30.09.2012	4.80%	8 180	287	7 991	99
BGN	18 495	31.08.2012	8.08%	-	-	6 467	-
<i>to companies under common indirect control</i>							
EUR	7 000	28.12.2012	4.50%	11 321	156	10 604	-
BGN	1 140	15.03.2012	8.08%	920	-	350	-
<i>to subsidiaries</i>							
EUR	2 770	21.01.2013	6.10%	5 896	479	-	-
BGN	600	02.12.2012	7.00%	251	1	151	1
USD	30	31.12.2012	3.50%	111	2	45	-
USD	25	31.12.2012	3.50%	41	2	39	1
USD	20	31.12.2012	3.50%	33	2	32	2
				<b>76 468</b>	<b>3 560</b>	<b>61 767</b>	<b>1 665</b>

The Company is a co-debtor under received bank loans and a guarantor of the following pharmaceutical trading companies before banks:

	Maturity	Currency	Amount		Status of the debt
			Original currency	BGN'000	30.06.2012 BGN'000
Sopharma Properties REIT	29.12.2020	EUR	30 000	58 675	57 371
Sopharma Trading AD	31.12.2012	EUR	10 000	19 558	19 558
Sopharma Trading AD	31.12.2012	EUR	8 434	16 495	16 472
Sopharma Trading AD	31.05.2013	EUR	4 000	3 912	7 387
Sopharma Trading AD	25.04.2013	EUR	3 000	5 867	5 867
SIA BRIZ	31.01.2013	EUR	2 050	4 009	3 685
Sopharma Trading AD	28.09.2013	EUR	2 000	3 912	2 789
Sopharma Trading AD	25.03.2013	EUR	2 000	3 912	2 765
Sopharma Trading AD	31.12.2012	BGN	3 732	3 732	2 536
Sopharma Trading AD	31.07.2012	EUR	2 050	4 009	2 474
Bulgarian Rose Sevtopolis AD	31.01.2015	EUR	1 617	3 163	1 241
Veta Pharma AD	31.11.2012	BGN	850	850	843
Sopharma Trading AD	25.10.2016	EUR	432	846	749
Energoinvestment AD	28.08.2012	BGN	2 000	2 000	518
Mineralcommerce AD	20.03.2017	EUR	100	196	196
Veta Pharma AD	31.11.2012	BGN	150	150	149
Sopharma Trading AD	25.05.2016	EUR	89	174	141
Sopharma Trading AD	31.12.2012	EUR	66	129	129
Sopharma Trading AD	25.07.2016	EUR	63	124	104

Unipharm AD	22.02.2013	EUR	50	98	<b>98</b>
Sopharma Trading AD	25.05.2016	EUR	41	80	<b>78</b>
Sopharma Trading AD	25.09.2016	EUR	22	42	<b>44</b>
Sopharma Trading AD	30.06.2013	EUR	1 675	3 276	<b>42</b>
Sopharma Trading AD	25.06.2016	EUR	23	45	<b>37</b>
Sopharma Trading AD	25.06.2016	EUR	22	43	<b>35</b>
Sopharma Trading AD	25.09.2016	EUR	15	29	<b>25</b>
Mineralcommerce AD	19.01.2014	EUR	25	49	<b>6</b>
				<b>135 326</b>	<b>125 333</b>

Sopharma AD concluded a contract with a supplier for the purchase and implementation of an integrated information system Microsoft Dynamics AX for the amount of BGN 3,700 thousand (EUR 1,892 thousand). The final term for implementation of the information system is 2012.

In 2011, the Company assumed a self-participation commitment at the amount of BGN 3,997 thousand under a contract for financing under Operating Programme "Development of the Competitiveness of the Bulgarian Economy" 2007 2013. The execution of the contract is envisaged to last 24 months and is related with financing the purchase of machinery and equipment.

---

Ognian Donev, PhD  
Executive Director